Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia

Sascha Dietrich, MD, Jennifer Hüllein, Michael Hundemer, Nicola Lehners, MD, Alexander Jethwa, David Capper, MD, Till Acker, MD, Boyan Garvalov, PhD, Mindaugas Andrulis, MD, Carolin Blume, Julia Meissner, MD, Stefan Fröhling, MD, Christof von Kalle, MD, Hanno Glimm, MD, Anthony D. Ho, MD, Thorsten Zenz, MD

Blood (2012) 120 (21): 4600.

https://doi.org/10.1182/blood.V120.21.4600.4600

Published: 2012

Journal Articles

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

Blood (2011) 118 (21): 3558.

https://doi.org/10.1182/blood.V118.21.3558.3558

Published: 2011

Journal Articles

Myeloid Leukemogenesis Driven by Aberrant CDX2 Expression Involves Transcriptional Repression of KLF4 and Deregulated PPARγ Signaling

Katrin Faber, Lars Bullinger, Angela Garding, Daniel Mertens, Daniela Martin, Daniel Walcher, Konstanze Döhner, Hartmut Döhner, MD, Stephen M. Sykes, Rainer Claus, Christoph Plass, Steven W. Lane, Claudia Scholl, Stefan Fröhling

Blood (2011) 118 (21): 1355.

https://doi.org/10.1182/blood.V118.21.1355.1355

Published: 2011

Journal Articles

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

Richard F. Schlenk, MD, Konstanze Döhner, MD, Michael Kneba, MD, Francesco del Valle, MD, Frank Hartmann, MD, Heinz Kirchen, MD, Elisabeth Koller, MD, Katharina Götze, MD, Jörg Th. Fischer, MD, Marianne Habdank, Daniela Späth, Silja Groner, Andrea Corbacioglu, Axel Benner, MSC, Stefan Fröhling, Hartmut Döhner

Blood (2007) 110 (11): 297.

https://doi.org/10.1182/blood.V110.11.297.297

Published: 2007

Journal Articles

CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.

Andrea Corbacioglu, PhD, Stefan Fröhling, MD, Corinna Mendla, Karina Eiwen, Marianne Habdank, Hartmut Döhner, MD, Richard F. Schlenk, MD, Konstanze Döhner, MD

Blood (2007) 110 (11): 363.

https://doi.org/10.1182/blood.V110.11.363.363

Published: 2007

Journal Articles

The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis.

Christian Thiede, MD, Clara D. Bloomfield, MD, Francesco Lo Coco, MD, Stefan Fröhling, MD, Wolfgang Hiddemann, MD, Jürgen Krauter, MD, Markus Schaich, MD, Susan P. Whitman, PhD, Guiseppe Saglio, MD, Konstanze Döhner, MD, Karsten Spiekermann, MD, Susanne Schnittger, MD, Arnold Ganser, MD, Gerhard Heil, MD, Thomas Büchner, MD, Hartmut Döhner, MD, Richard A. Larson, MD, Gerhard Ehninger, MD

Blood (2007) 110 (11): 761.

https://doi.org/10.1182/blood.V110.11.761.761

Published: 2007

Journal Articles

Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).

Andrea Corbacioglu, PhD, Stefan Fröhling, MD, Peter Paschka, MD, Guido Marcucci, MD, Andreas Anhalt, Katja Urlbauer, Jürgen Krauter, MD, Richard Larson, MD, Krzysztof Mrózek, MD, Amy S. Ruppert, MD, Arnold Ganser, MD, Michael A. Caligiuri, MD, Hartmut Döhner, MD, Richard F. Schlenk, MD, Clara D. Bloomfield, MD, Konstanze Döhner, MD

Blood (2007) 110 (11): 762.

https://doi.org/10.1182/blood.V110.11.762.762

Published: 2007

Journal Articles

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B

Stefan Fröhling, Richard F. Schlenk, Sabine Kayser, Martina Morhardt, Axel Benner, Konstanze Döhner, Hartmut Döhner, for the German-Austrian AML Study Group

Blood (2006) 108 (10): 3280–3288.

https://doi.org/10.1182/blood-2006-04-014324

Published: 2006

Journal Articles

JAK2 T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

Thomas Mercher, Gerlinde Wernig, Sandra A. Moore, Ross L. Levine, Ting-Lei Gu, Stefan Fröhling, Dana Cullen, Roberto D. Polakiewicz, Olivier A. Bernard, Titus J. Boggon, Benjamin H. Lee, D. Gary Gilliland

Blood (2006) 108 (8): 2770–2779.

https://doi.org/10.1182/blood-2006-04-014712

Published: 2006

Includes: Supplemental data

Journal Articles

Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7

Stefan Fröhling, Daniel B. Lipka, Sabine Kayser, Claudia Scholl, Richard F. Schlenk, Hartmut Döhner, D. Gary Gilliland, Ross L. Levine, Konstanze Döhner

Blood (2006) 107 (3): 1242–1243.

https://doi.org/10.1182/blood-2005-09-3644

Published: 2006

Journal Articles

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

Konstanze Döhner, Richard F. Schlenk, Marianne Habdank, Claudia Scholl, Frank G. Rücker, Andrea Corbacioglu, Lars Bullinger, Stefan Fröhling, Hartmut Döhner, for the AML Study Group (AMLSG)

Blood (2005) 106 (12): 3740–3746.

https://doi.org/10.1182/blood-2005-05-2164

Published: 2005

Journal Articles

Pretreatment Cytogenetic Abnormalities Are Predictive of Induction Success, Cumulative Incidence of Relapse and Overall Survival in Patients >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia.

Richard F. Schlenk, MD, Sabine Kayser, Martina Morhardt, Konstanze Döhner, MD, Hartmut Döhner, MD, Stefan Fröhling, MD

Blood (2005) 106 (11): 3293.

https://doi.org/10.1182/blood.V106.11.3293.3293

Published: 2005

Journal Articles

Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.

Richard F. Schlenk, MD, Martin Bommer, MD, Mathias Schmid, MD, Stefan Fröhling, MD, Katrin Lehmann, Silja Groner, Rainer Hann, Jürgen Krauter, MD, Konstanze Döhner, MD, Arnold Ganser, MD, Martin Göttlicher, MD, Hartmut Döhner, MD

Blood (2005) 106 (11): 2800.

https://doi.org/10.1182/blood.V106.11.2800.2800

Published: 2005

Journal Articles

Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.

Richard F. Schlenk, MD, Andrea Corbacioglu, PhD, Stefan Fröhling, MD, Juan Du, MD, Daniela Späth, Irina Schäfer, Jürgen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Konstanze Döhner, MD, for the German-Austrian, AML Study Group (AMLSG)

Blood (2005) 106 (11): 2352.

https://doi.org/10.1182/blood.V106.11.2352.2352

Published: 2005

Journal Articles

Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3 -ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.

Richard F. Schlenk, MD, Jürgen Krauter, MD, Stefan Fröhling, MD, Daniela Späth, Irina Schäfer, MD, Stefan Hein, Hartmut Döhner, MD, Arnold Ganser, MD, Konstanze Döhner, MD, for the German-Austrian AML Study Group (AMLSG)

Blood (2005) 106 (11): 2353.

https://doi.org/10.1182/blood.V106.11.2353.2353

Published: 2005

Journal Articles

Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM)

Konstanze Döhner, Karen Tobis, Tobias Bischof, Stefan Hein, Richard F. Schlenk, Stefan Fröhling, Hartmut Döhner

Blood (2003) 102 (10): 3850–3851.

https://doi.org/10.1182/blood-2003-08-2654

Published: 2003

Journal Articles

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm

Stefan Fröhling, Richard F. Schlenk, Jochen Breitruck, Axel Benner, Sylvia Kreitmeier, Karen Tobis, Hartmut Döhner, Konstanze Döhner

Blood (2002) 100 (13): 4372–4380.

https://doi.org/10.1182/blood-2002-05-1440

Published: 2002

Journal Articles

Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders

Konstanze Döhner, Jill Brown, Ute Hehmann, Claudia Hetzel, Janet Stewart, Gordon Lowther, Claudia Scholl, Stefan Fröhling, Antonio Cuneo, Lap C. Tsui, Peter Lichter, Stephen W. Scherer, Hartmut Döhner

Blood (1998) 92 (11): 4031–4035.

https://doi.org/10.1182/blood.V92.11.4031

Published: 1998

Journal Articles

Molecular Cytogenetic Delineation of Deletions and Translocations Involving Chromosome Band 7q22 in Myeloid Leukemias

Konstanze Fischer, Stefan Fröhling, Stephen W. Scherer, Jill McAllister Brown, Claudia Scholl, Stephan Stilgenbauer, Lap-Chee Tsui, Peter Lichter, Hartmut Döhner

Blood (1997) 89 (6): 2036–2041.

https://doi.org/10.1182/blood.V89.6.2036

Published: 1997

NARROW

Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

Myeloid Leukemogenesis Driven by Aberrant CDX2 Expression Involves Transcriptional Repression of KLF4 and Deregulated PPARγ Signaling

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.

The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis.

Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B

JAK2 T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

Pretreatment Cytogenetic Abnormalities Are Predictive of Induction Success, Cumulative Incidence of Relapse and Overall Survival in Patients >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia.

Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.

Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.

Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3 -ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.

Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM)

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm

Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders

Molecular Cytogenetic Delineation of Deletions and Translocations Involving Chromosome Band 7q22 in Myeloid Leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only